DIRS.INFO The most relevant business & tech news

☆ Generic drugs are most likely to face shortages due to market failures in affordability
▼ + stars: | 2023-03-29 | by ( Meg Tirrell | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailGeneric drugs are most likely to face shortages due to market failures in affordabilityCNBC's Meg Tirrell joins 'Closing Bell Overtime' to discuss growing pharmaceutical shortages, increasing debt hindering generic drug availability, and more.

☆ Antibiotics in short supply: U.S. drug shortages reach historic high
▼ + stars: | 2023-03-28 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAntibiotics in short supply: U.S. drug shortages reach historic highHosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy. Tune in Monday through Friday at 7 p.m. ET on CNBC. CNBC's Meg Tirrell reports on the antibiotic shortage hitting the U.S.

☆ Shanghai exchange cancels Syngenta IPO hearing -filing
▼ + stars: | 2023-03-28 | by ( ) www.reuters.com time to read: +1 min

HONG KONG, March 28 (Reuters) - The Shanghai Stock Exchange has cancelled a hearing to review Swiss agrichemicals and seeds group Syngenta's initial share offering (IPO) plan, a filing posted on the exchange showed. Syngenta, which planned to raise 65 billion yuan ($9.44 billion) in its Shanghai flotation, was bought for $43 billion by ChemChina in 2017 and folded into Sinochem Holdings Corp in 2021. The Shanghai exchange, which planned to conduct the hearing on Wednesday, did not provide a reason for the cancellation. Companies planning IPOs on the exchange need to appear before a panel for a hearing as a requirement for proceeding with their listing. ($1 = 6.8821 Chinese yuan renminbi)Reporting by Meg Shen and Twinnie Siu; editing by Jason Neely, Jane Merriman and Louise HeavensOur Standards: The Thomson Reuters Trust Principles.

☆ Antibiotics in short supply: U.S. drug shortages hit record level
▼ + stars: | 2023-03-28 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAntibiotics in short supply: U.S. drug shortages hit record levelCNBC’s Meg Tirrell joins ‘Closing Bell: Overtime’ to report on why there's a shortage of antibiotics in the U.S.

☆ BYD posts 11-fold jump in Q4 profit -filing
▼ + stars: | 2023-03-28 | by ( ) www.reuters.com time to read: +2 min

SHANGHAI/BEIJING, March 28 (Reuters) - Chinese electric vehicle giant BYD Co Ltd (002594.SZ) reported an 11-fold increase in fourth-quarter profit as it extended its lead in the domestic market with a wide range of products. Net profit for October-December came in at 7.3 billion yuan ($1.06 billion) versus 602 million yuan a year earlier. For the whole of 2022, net profit increased 446% to 16.6 billion yuan, said the company, which is 12% owned by Warren Buffett's Berkshire Hathaway (BRKa.N). Its battery installation volume ranked the second globally in Janaury with 17.6% market share, exceeding LG Energy Solutions, according to SNE Research. ($1 = 6.8756 Chinese yuan renminbi)Reporting by Zhang Yan, Ella Cao and Meg Shen; editing by Jason Neely, Jonathan Oatis and Angus MacSwanOur Standards: The Thomson Reuters Trust Principles.

☆ China urges Apple to strengthen data security
▼ + stars: | 2023-03-28 | by ( ) www.reuters.com time to read: 1 min

HONG KONG, March 28 (Reuters) - China has urged Apple (AAPL.O) to strengthen its data security and personal privacy protection, the country's state planner said in a statement on Tuesday. Chairman of National Development and Reform Commission Zheng Shanjie made the comments when he met Apple CEO Tim Cook on Monday, the statement said. Reporting by Ella Cao and Meg Shen, Editing by Louise HeavensOur Standards: The Thomson Reuters Trust Principles.

☆ Regeneron's Dupixent shows promise as COPD treatment
▼ + stars: | 2023-03-23 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailRegeneron's Dupixent shows promise as COPD treatmentCNBC's Meg Tirrell joins 'Closing Bell' to report that Regeneron's drug Dupixent has shown promise in treating COPD during phase 3 results.

☆ Sen. Bernie Sanders grills Moderna CEO over Covid vaccine prices during hearing
▼ + stars: | 2023-03-22 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSen. Bernie Sanders grills Moderna CEO over Covid vaccine prices during hearingCNBC's Meg Tirrell reports on the Senate hearing on drug prices, which featured an exchange between Sen. Bernie Sanders and Moderna CEO Stéphane Bancel.

☆ China fines Deloitte $31 mln for auditing negligence
▼ + stars: | 2023-03-18 | by ( ) www.reuters.com time to read: +2 min

BEIJING, March 17 (Reuters) - China has fined auditing firm Deloitte 211.9 million yuan ($30.8 million) for failing to perform its duty in assessing the asset quality of China Huarong Asset Management Co Ltd (2799.HK), the finance ministry said on its website on Friday. Deloitte's Beijing operations also will be suspended for three months, the ministry said in a statement. Deloitte said it respects and accepts the ministry's decision, according to a statement published on its website. "We regret that, in this matter, the MOF considers certain aspects of our work fell below the required auditing standards," it said. In a separate statement, Huarong said the company and its seven subsidiaries had received a 100,000 yuan fine each.

☆ Independent bookstores once considered Barnes & Noble the enemy, but its CEO loves small bookstores so much, he owns 9 of his own
▼ + stars: | 2023-03-17 | by ( Avery Hartmans | ) www.businessinsider.com time to read: +3 min

Barnes & Noble's CEO owns nine independent bookstores scattered throughout London. But back in the 1990s, the book retailer was considered the enemy of small bookstores everywhere. That was before Barnes & Noble went into decline — these days, it's in the midst of a revamp. Chains like Barnes & Noble were the enemy of anyone who truly loved books, according to the film. Daunt now oversees roughly 600 Barnes & Noble stores across the US, as well as 100 Paper Source stores and nearly 300 Waterstones shops in the UK and Europe, according to Barnes & Noble.

☆ SVB fallout: The impacts on the biotech sector
▼ + stars: | 2023-03-13 | by ( Meg Tirrell | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSVB fallout: The impacts on the biotech sectorCNBC's Meg Tirrell reports on how the SVB fallout could impact biotech investors.

☆ Chinese EV comptition hots up as BYD offers discounts
▼ + stars: | 2023-03-09 | by ( ) www.reuters.com time to read: +1 min

[1/2] BYD electric vehicles (EV) are displayed at a car dealership in Shanghai, China, February 3, 2023. The discounts will be for buyers who place orders for the Song Plus and Seal models between March 10 and March 31, the company said on its social media account. In return for an 88 yuan ($12.64) deposit, buyers for a Seal EV can get 8,888 yuan deducted from the price, while for Song Plus models, the discount is 6,888 yuan. It sold 34,621 Song Plus SUVs and 14,372 Seal sedans in the first two months, according to China Passenger Car Association. The car association data showed Tesla (TSLA.O) sold 39,710 Model Ys and 21,056 Model 3s in January and February combined.

☆ New weight loss drugs will help tackle America's obesity epidemic, says Dr. Scott Gottlieb
▼ + stars: | 2023-03-07 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNew weight loss drugs will help tackle America's obesity epidemic, says Dr. Scott GottliebDr. Scott Gottlieb, former FDA commissioner, and CNBC's Meg Tirrell join 'Power Lunch' to discuss WeightWatchers upcoming telehealth deal, new weight loss drugs coming to market and regulatory considerations associated with long-term medicine use.

☆ WW International CEO on weight loss drugs: Still critical you make the right lifestyle changes
▼ + stars: | 2023-03-07 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWW International CEO on weight loss drugs: Still critical you make the right lifestyle changesCNBC's Meg Tirrell talks with Sima Sistani, WW International CEO, on 'Closing Bell: Overtime' to discuss the company's stock surge after announcing it had acquired Sequence, a telehealth platform that helps treat obesity.

☆ China opposes U.S. adding Chinese firms to trade blacklist
▼ + stars: | 2023-03-03 | by ( ) www.reuters.com time to read: 1 min

HONG KONG, March 3 (Reuters) - China opposes the United States adding several Chinese firms to its trade blacklist, China's commerce ministry said on Friday. China urges the United States to stop using any excuse to suppress Chinese firms, the ministry said in a statement posted on its website. The U.S. Commerce Department, which oversees export controls, recently added two units of genetics company BGI (300676.SZ) to the export control list. Reporting by Meg Shen and Twinnie SiuOur Standards: The Thomson Reuters Trust Principles.

☆ A fund manager who's beaten 99% of his peers over the last decade shares 5 energy stocks he's betting on right now as 'oil and gas profits could become one of the only games in town' during a recessio
▼ + stars: | 2023-03-02 | by ( William Edwards | ) www.businessinsider.com time to read: +3 min

Energy stocks still have more upside even after their big run, says Bill Smead. Energy stocks have soared since their pandemic lows, with the Energy Select Sector SPDR Fund (XLE) up 230% since March 2020 compared to the S&P 500's 71%. Further, Smead said an incoming recession could wipe out profits in other industries, leaving investors to flock to the oil industry. Nothing could be better than producing addictive fossil fuel energy at higher and higher prices for the next decade." 5 energy stocks to watchWhile Smead is bullish on energy broadly, he especially likes firms that aren't giants in the industry.

☆ The quality of your clinical data drives everything, says Reata Pharma CEO Warren Huff
▼ + stars: | 2023-03-02 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThe quality of your clinical data drives everything, says Reata Pharma CEO Warren HuffWarren Huff, CEO of Reata Pharmaceuticals, and CNBC's Meg Tirrell join 'Power Lunch' to discuss Reata's new drug for treating a rare neurological disorder receiving FDA approval.

☆ China willing to play constructive role in debt talks
▼ + stars: | 2023-03-01 | by ( ) www.reuters.com time to read: +1 min

BEIJING, March 1 (Reuters) - China is willing to "constructively" participate in solving the debt problems of relevant countries under a multilateral framework, its Premier Li Keqiang said on Wednesday. China, the world's largest bilateral creditor, has criticised multilateral lenders for not accepting losses, or haircuts, on loans to low-income countries while Beijing is being asked to do so on credit it has extended on its own. In a phone call with International Monetary Fund Managing Director Kristalina Georgieva, Li said that solving the debt problems of low-income countries requires the participation of all creditors, according to a China State Department statement. China is a major lender to high-debt countries, such as Ghana and Zambia. Reporting by Meg Shen and Ryan Woo Ediing by Tomasz JanowskiOur Standards: The Thomson Reuters Trust Principles.

☆ Eli Lilly cuts insulin prices by 70%
▼ + stars: | 2023-03-01 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly cuts insulin prices by 70%CNBC's Meg Tirrell joins 'The Exchange' to discuss Eli Lilly's decision to set insulin price caps, the motivations behind the company's decision, and whether or not other insulin producers will join them in cutting prices.

☆ Eli Lilly CEO on slashing insulin prices, approval timelines for weight-loss and Alzheimer's drugs
▼ + stars: | 2023-03-01 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO on slashing insulin prices, approval timelines for weight-loss and Alzheimer's drugsCNBC's Meg Tirrell and David Ricks, Eli Lilly CEO, joins 'Closing Bell: Overtime' to discuss the company's decision to slash insulin prices. He also discusses his economic outlook and the timeline for approval of drugs in its pipeline.

☆ FDA advisory panel votes in favor of adult RSV vaccine from GSK PLC
▼ + stars: | 2023-03-01 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisory panel votes in favor of adult RSV vaccine from GSK PLCCNBC's Meg Tirrell joins 'Power Lunch' to discuss GSK PLC's RSV vaccine receiving FDA support, ongoing questions around the drug's approval and the timeline for the drug to be available for children.

☆ FDA advisers support Pfizer's RSV vaccine for older adults
▼ + stars: | 2023-02-28 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisers support Pfizer's RSV vaccine for older adultsCNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on FDA support for a Pfizer RSV vaccine for adults 65 and over.

☆ Novavax stock down on concern over whether the company can continue
▼ + stars: | 2023-02-28 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovavax stock down on concern over whether the company can continueCNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on Novavax's warning that it may not be able to continue as a company. Also, Sarepta shares rise on FDA signaling no advisory meeting on gene therapy.

☆ As we work more on the human genome project, the market for rare disease therapies grows, says Nord CEO
▼ + stars: | 2023-02-28 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAs we work more on the human genome project, the market for rare disease therapies grows, says Nord CEOCNBC's Meg Tirrell, Nord CEO Peter Saltonstall and Boston Children's Hospital's Dr. Olaf Bodamer join 'Power Lunch' to discuss pharmaceutical companies developing treatments for rare disease, the growth expectations for rare disease pharmaceuticals and the state of competition in the rare disease treatment space.

☆ A generation of high-profile women tech leaders have stepped aside. What’s next?
▼ + stars: | 2023-02-24 | by ( Catherine Thorbecke | ) edition.cnn.com time to read: +7 min

The tech industry has now lost an entire generation of trailblazing women leaders and replaced them mostly with men. And in the wake of the pandemic, women leaders in corporate America more broadly are more likely than ever to quit, according to the most recent Women in the Workplace report from McKinsey & Company and LeanIn.Org. Now that she’s departing, Big Tech is facing a new reckoning over its failure to promote and support women leaders, and what this could mean for the next generation of women in the industry. “Without women in the C-suite who have come before them, it could make this transition period tougher for next generation women leaders,” Kray said. “I think that what she achieved and what she modeled will be something that will live on beyond the fact that now we don’t have a female Big Tech CEO.”

Search resuls for: "Meg"

25 mentions found